These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 23551956)
1. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial. Zhang L; Zhang Z; Chen Y; Qin X; Zhou H; Zhang C; Sun H; Tang R; Zheng J; Yi L; Deng L; Li J Int J Neuropsychopharmacol; 2013 Aug; 16(7):1529-37. PubMed ID: 23551956 [TBL] [Abstract][Full Text] [Related]
2. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Parkinson Study Group Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852 [TBL] [Abstract][Full Text] [Related]
3. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996 [TBL] [Abstract][Full Text] [Related]
4. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G; Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866 [TBL] [Abstract][Full Text] [Related]
5. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. Hoy SM; Keating GM Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. Tolosa E; Stern MB Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study. Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109 [TBL] [Abstract][Full Text] [Related]
8. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Stocchi F; Rabey JM Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884 [TBL] [Abstract][Full Text] [Related]
9. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease. Hattori N; Takeda A; Takeda S; Nishimura A; Nakaya R; Mochizuki H; Nagai M; Takahashi R J Neural Transm (Vienna); 2019 Mar; 126(3):289-297. PubMed ID: 30635744 [TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656 [TBL] [Abstract][Full Text] [Related]
13. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. Smith KM; Eyal E; Weintraub D; JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207 [TBL] [Abstract][Full Text] [Related]
14. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ; J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804 [TBL] [Abstract][Full Text] [Related]
15. Rasagiline: a review of its use in the management of Parkinson's disease. Oldfield V; Keating GM; Perry CM Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172 [TBL] [Abstract][Full Text] [Related]
16. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials. Elmer LW Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501 [TBL] [Abstract][Full Text] [Related]
17. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages]. Pagonabarraga J; Rodríguez-Oroz MC Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679 [TBL] [Abstract][Full Text] [Related]
18. Rasagiline: a guide to its use in Parkinson's disease. Keating GM; Lyseng-Williamson KA; Hoy SM CNS Drugs; 2012 Sep; 26(9):781-5. PubMed ID: 22834567 [TBL] [Abstract][Full Text] [Related]
19. Rasagiline for the treatment of Parkinson's disease: an update. Stocchi F; Fossati C; Torti M Expert Opin Pharmacother; 2015; 16(14):2231-41. PubMed ID: 26364897 [TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials. Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]